Dyno Therapeutics launches Dyno-yp2, a top-performing TfR1-mediated AAV capsid, to further diversify CNS delivery portfolio ...

A researcher is planning on investigating potential treatments aimed at the root causes of type 1 diabetes. At the (MUSC), ...

Therapies market, valued at USD 16.7 million in 2024, is expected to register robust revenue CAGR of 44.6%.Request free copy of this report: 13, 2026- The growing incidence of autoimmune disorders ...

In the battle against type 1 diabetes (T1D), one researcher at the Medical University of South Carolina (MUSC) is leading a ...

The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs.

Birth control pills are a highly effective way to prevent pregnancy, but some foods and supplements can interfere with how ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

Adjusted EBITDA -- $1.1 million for the period, compared to an adjusted loss of $1.4 million in the same quarter last year.

Alzheimer's disease (AD) is a serious neurodegenerative disease largely affecting older adults. Apart from age, it also shows sex-based differences, with women being more at risk. However, the origin ...

ProQR is developing RNA therapies based on its proprietary Axiomer RNA editing technology platform. The ongoing Phase 1 study of AX-0810, which targets NTCP for cholestatic diseases such as primary ...

A human-specific NOVA1 variant changed mouse vocalizations, potentially providing insights into the evolution of language. Darnell said the switch to the new NOVA1 variant likely occurred between ...